Apolipoproteins are and better risk indicators of heart infarction;Apolipoproteiner nya och bättre riskindikatorer för hjärtinfarkt

Lakartidningen

Volumn 101, Issue 13, 2004, Pages 1188-1194

  Walldius, Göran ^a,b   Jungner, Ingmar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE MARKER; HEART INFARCTION; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; REVIEW;

APOLIPOPROTEINS A; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS;

EID: 1842861557     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on decision, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97.
2. Läkemedelsverket. Behandlingsrekommendation. Behandling med lipidsänkande läkemedel vid prevention av hjärt- kärlsjukdomar. Information från Läkemedelsverket 2003;14(4):9-68. (http://www.mpa.se)
3. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
4. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361: 777-80.
5. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.
6. Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular risk - clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 2002;26:544-50.
7. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: The twin achilles heels of the Friedewald Formula. Clin Biochem 2003;36:499-504.
8. Rubies-Prat J, Reverter JL, Senti M, Pedro-Botet J, Salinas I, Lucas A, et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993;16:1081-6.
9. Nauck M, Warnick GR, Rifai N. Methods for measurements of LDL-cholesterol: A critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.
10. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apoB and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-22.
11. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Benard PM, Dagenais GR, et al. Apoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 1996;94:273-8.
12. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
13. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92.
14. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998;44:1641-9.
15. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:515-23.
16. Grundy SM. Low-density lipoprotein, non-high density lipoprotein, and apolipoprotein B as targets of lipid lowering therapy. Circulation 2002;106:2526-9.
17. Ose L. Kan apolipoproteinmålinger erstatte vanlige lipidbestemmelser? Information från Läkemedelsverket 2003;14(4):43-5-. (http://www.mpa.se)
18. Conroy RM, Pyörälä AP, Fitzgerald S, Sans A, Menotti G, De Backer D, et al. Estimation of ten-year risk factor cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
19. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice? Am J Cardiol 2002;90:48i-54i.
20. Packard CJ. Apolipoproteins: the new prognostic indicator? Eur Heart J Supplements 2003;5/suppl D:D9-D16.
21. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Int Med 2004;255:188-205.